MX2022010593A - Composiciones tópicas de diclofenaco y métodos. - Google Patents

Composiciones tópicas de diclofenaco y métodos.

Info

Publication number
MX2022010593A
MX2022010593A MX2022010593A MX2022010593A MX2022010593A MX 2022010593 A MX2022010593 A MX 2022010593A MX 2022010593 A MX2022010593 A MX 2022010593A MX 2022010593 A MX2022010593 A MX 2022010593A MX 2022010593 A MX2022010593 A MX 2022010593A
Authority
MX
Mexico
Prior art keywords
methods
topical diclofenac
diclofenac compositions
compositions
topical
Prior art date
Application number
MX2022010593A
Other languages
English (en)
Inventor
Dario N R Carrara
Amaud Grenier
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2022010593A publication Critical patent/MX2022010593A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en el presente documento composiciones farmacéuticas que comprenden diclofenaco y métodos terapéuticos para su uso eficaz mediante una administración de una vez al día.
MX2022010593A 2020-02-27 2021-02-25 Composiciones tópicas de diclofenaco y métodos. MX2022010593A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982589P 2020-02-27 2020-02-27
PCT/NL2021/050125 WO2021172987A1 (en) 2020-02-27 2021-02-25 Topical diclofenac compositions and methods

Publications (1)

Publication Number Publication Date
MX2022010593A true MX2022010593A (es) 2022-12-13

Family

ID=74858737

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010593A MX2022010593A (es) 2020-02-27 2021-02-25 Composiciones tópicas de diclofenaco y métodos.

Country Status (9)

Country Link
US (1) US20230157979A1 (es)
EP (1) EP4110320A1 (es)
JP (1) JP2023515539A (es)
CN (1) CN115279360A (es)
AU (1) AU2021228521A1 (es)
BR (1) BR112022016887A2 (es)
CA (1) CA3169241A1 (es)
MX (1) MX2022010593A (es)
WO (1) WO2021172987A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1670433T3 (pl) 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
WO2012087749A1 (en) * 2010-12-20 2012-06-28 Polytherapeutics, Inc. Composition for transdermal administration of non-steroidal anti-inflammatory drug
US9713590B2 (en) * 2011-07-28 2017-07-25 Cadila Healthcare Limited Method for treatment of pain and inflammation
EP3275466A1 (en) * 2012-07-12 2018-01-31 Ferring B.V. Diclofenac formulations
US9468618B2 (en) * 2014-12-12 2016-10-18 Lupin Atlantis Holdings Sa Topical pharmaceutical gel composition of diclofenac sodium

Also Published As

Publication number Publication date
AU2021228521A1 (en) 2022-10-13
EP4110320A1 (en) 2023-01-04
JP2023515539A (ja) 2023-04-13
CN115279360A (zh) 2022-11-01
WO2021172987A1 (en) 2021-09-02
CA3169241A1 (en) 2021-09-02
US20230157979A1 (en) 2023-05-25
BR112022016887A2 (pt) 2022-10-18

Similar Documents

Publication Publication Date Title
JOP20200268A1 (ar) تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
CR20220316A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
WO2020236825A3 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
JOP20210045A1 (ar) مترافقات جسم مضاد وعقار هربوكسيديين وطرق استخدامها
MX2020011295A (es) Tratamiento de dermatitis atopica.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
NZ609727A (en) A combination composition comprising ibuprofen and paracetamol
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2020007971A (es) Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
EA202190171A1 (ru) Применение грамотрицательных видов для лечения атопического дерматита
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
EA201591603A1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
MX2022010593A (es) Composiciones tópicas de diclofenaco y métodos.
TW201642854A (en) Fixed dose combination for pain relief without edema
WO2019067768A3 (en) FIXED DOSE COMBINATION FORMULATIONS FOR THE TREATMENT OF PAIN
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2014005152A (es) Composicion farmaceutica para el tratamiento de alopatias relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol.
WO2018136647A3 (en) Therapeutic use of beta-lactams in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels